Neuromyelitis Optica Spectrum Disorder (NMOSD): Clinical Features, Diagnosis, and Treatment
Neuromyelitis optica spectrum disorder (NMOSD), formerly Devic disease, is an autoimmune astrocytopathy targeting aquaporin-4 (AQP4) water channels on astrocytes. It is distinct from multiple sclerosis (MS) and requires specific immunotherapy to prevent devastating relapses.
Pathophysiology
- AQP4-IgG (NMO-IgG): Pathogenic autoantibody in 70–80% of NMOSD. Binds astrocytic AQP4 → complement activation (CDC), antibody-dependent cellular cytotoxicity (ADCC), granulocyte infiltration → astrocyte loss, demyelination, neuronal injury.
- Seronegative NMOSD: ~20–30%; some have anti-MOG antibodies (MOGAD — distinct entity), others truly double-seronegative.
Core Clinical Characteristics (2015 IPND Criteria)
Diagnosis requires ≥1 core characteristic + AQP4-IgG positivity, or ≥2 core characteristics (one must be optic neuritis, acute myelitis, or area postrema syndrome) + MRI requirements if seronegative.
- Optic neuritis: Typically bilateral, severe, longitudinally extensive (involving >1/2 optic nerve), chiasmal involvement common. Poor recovery without treatment.
- Acute myelitis: Longitudinally extensive transverse myelitis (LETM) — ≥3 vertebral segments. Central cord involvement. Flaccid paralysis, sensory level, autonomic dysfunction (neurogenic bladder/bowel).
- Area postrema syndrome: Intractable nausea, vomiting, hiccups (dorsal medulla). Often presenting feature.
- Acute brainstem syndrome: Periaqueductal lesions → oculomotor, vestibular, respiratory centers.
- Symptomatic narcolepsy / diencephalic syndrome: Hypothalamic lesions.
- Symptomatic cerebral syndrome: Large hemispheric lesions (unlike MS).
Diagnostic Workup
- Serum AQP4-IgG: Cell-based assay (gold standard). ELISA has high false-positive rate.
- MRI Brain/Orbits/Spine: LETM, optic nerve T2 hyperintensity >1/2 length, periependymal brain lesions (area postrema, hypothalamus, brainstem).
- CSF: Pleocytosis (often >50 WBC, neutrophilic), elevated protein, low glucose (unlike MS). Oligoclonal bands rare (<20%).
- MOG-IgG: Rule out MOGAD (better prognosis, different treatment).
Acute Relapse Management
- High-dose IV methylprednisolone: 1g daily ×3–5 days — first-line.
- Plasma exchange (PLEX): 5–7 exchanges if incomplete response to steroids — critical for severe myelitis/ON. Early initiation (<2 weeks) improves outcomes.
- IVIG: Alternative if PLEX unavailable/contraindicated.
Long-Term Immunosuppression (Relapse Prevention)
All AQP4+ patients require maintenance therapy. Relapse risk high without treatment; each relapse causes cumulative disability.
- Eculizumab (Soliris): Anti-C5 complement inhibitor; FDA-approved 2019. IV q2wk. Reduces relapse risk >90%. Meningococcal vaccination required.
- Satralizumab (Enspryng): Anti-IL-6 receptor; SC q4wk. FDA-approved 2020. Effective in AQP4+.
- Inebilizumab (Uplizna): Anti-CD19 B-cell depletion; IV q6mo. FDA-approved 2020.
- Rituximab: Anti-CD20; off-label but widely used, extensive real-world data. IV q6mo. Monitor IgG, B-cells.
- Azathioprine / Mycophenolate / Tocilizumab: Older agents, less robust evidence, used if newer agents inaccessible.
Symptomatic Management
- Neuropathic pain: gabapentin, pregabalin, duloxetine
- Spasticity: baclofen, tizanidine, botulinum toxin
- Bladder/bowel: anticholinergics, clean intermittent catheterization
- Fatigue: amantadine, modafinil, energy conservation
- Depression/anxiety: SSRIs, counseling
Prognosis
Without treatment: 50% wheelchair-bound or blind at 5 years. With modern immunosuppression: relapse-free survival >80% at 2–3 years. Early diagnosis and AQP4-targeted therapy are transformative.
Key Differentiators from MS
| Feature | NMOSD | MS |
|---|---|---|
| Antibody | AQP4-IgG | None specific (OCB+) |
| Optic neuritis | Bilateral, severe, LETM | Unilateral, mild-moderate |
| Myelitis | LETM (≥3 segments) | Short segment (<3) |
| Brain MRI | Periependymal, hypothalamic | Periventricular, juxtacortical |
| CSF OCBs | Rare | Common (>90%) |
Eye & Vision Disorders - Related Articles
- Understanding Sphere Power in Contact Lens Prescriptions
- Electric Sunglasses: Durable Italian Style & UV Protection
- Understanding & Managing High Eye Pressure (Glaucoma)
- Understanding Total Blindness: Causes, Definition, Impact, and Technology
- Tinted Lenses: Benefits, Uses & Considerations
- Understanding Bright Spots in Your Vision: Causes & When to Worry
- DIY Eyeglass Lens Replacement: A Step-by-Step Guide
